Mirati Therapeutics, Inc.
MRTXDrugs in Pipeline
13
Phase 3 Programs
7
Upcoming Catalysts
7
Next Catalyst
Jun 1, 2026
11wMarket Overview
Stock performance and key metrics
7 upcoming, 0 past
Enfortumab Vedotin-Ejfv
Advanced or Metastatic Solid Malignancies
Docetaxel
Metastatic Non-Squamous Non-Small Cell Lung Cancer
Sitravatinib
Clear Cell Renal Cell Carcinoma
MRTX849
Advanced Cancer
Adagrasib
Carcinoma, Non-Small-Cell Lung
Pembrolizumab
Advanced Non-Small Cell Lung Cancer
Cetuximab
Advanced Colorectal Cancer
Adagrasib oral dose of 400 mg twice daily tablets
Advanced NSCLC
MGCD265
Non-Small Cell Lung Cancer
Gemcitabine
Tumors
MRTX0902
Solid Tumor
MGCD0103
Lymphocytic Leukemia, Chronic
Mocetinostat
Myelodysplastic Syndrome
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Enfortumab Vedotin-Ejfv | Phase 3 | Advanced or Metastatic Solid Malignancies | - | - |
Docetaxel | Phase 3 | Metastatic Non-Squamous Non-Small Cell Lung Cancer | - | - |
Sitravatinib | Phase 3 | Clear Cell Renal Cell Carcinoma | - | - |
MRTX849 | Phase 3 | Advanced Cancer | - | - |
Adagrasib | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
Pembrolizumab | Phase 3 | Advanced Non-Small Cell Lung Cancer | - | - |
Cetuximab | Phase 3 | Advanced Colorectal Cancer | - | - |
Adagrasib oral dose of 400 mg twice daily tablets | Phase 2 | Advanced NSCLC | - | - |
MGCD265 | Phase 2 | Non-Small Cell Lung Cancer | - | - |
Gemcitabine | Phase 2 | Tumors | - | - |
MRTX0902 | Phase 2 | Solid Tumor | - | - |
MGCD0103 | Phase 2 | Lymphocytic Leukemia, Chronic | - | - |
Mocetinostat | Phase 2 | Myelodysplastic Syndrome | - | - |